Alzinova AB (publ) (STO:ALZ)

Market Cap	78.24M
Revenue (ttm)	26.12M
Net Income (ttm)	-26.94M
Shares Out	104.32M
EPS (ttm)	-0.29
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	484,607
Average Volume	606,081
Open	0.7610
Previous Close	0.7500
Day's Range	0.7360 - 0.7760
52-Week Range	0.7300 - 3.8200
Beta	1.43
RSI	27.44
Earnings Date	Feb 26, 2026

About Alzinova AB

Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer’s disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer’s disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aβ42, called oligomers, which are considered to be the underlying cause of Alzheimer’s disease; and a humanized version of ALZ-201 in patients with Alzheimer’s d...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2011
• Employees: 5
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: ALZ

Financial Performance

In 2024, Alzinova AB's revenue was 16.81 million, a decrease of -15.41% compared to the previous year's 19.87 million. Losses were -20.55 million, 24.7% more than in 2023.